Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Apr 28 2025 | Impulse Dynamics®’ INTEGRA-D Trial Completes Efficacy Phase Industry News In The News Industry Read More Apr 22 2025 | New Joint Scientific Statement on Ejection Fraction Released by Leading Heart Failure Organizations HFSA News In The News Journal of Cardiac Failure Press Release Research Statement Read More Apr 18 2025 | U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications Industry News In The News Industry Read More Apr 17 2025 | Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial Industry News In The News Industry Read More Apr 15 2025 | New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival Industry News In The News Industry Read More Pagination First page « First Previous page ‹ Previous … Page 16 Page 17 Page 18 Page 19 Current page 20 Page 21 Page 22 Page 23 Page 24 … Next page Next › Last page Last »
Apr 28 2025 | Impulse Dynamics®’ INTEGRA-D Trial Completes Efficacy Phase Industry News In The News Industry Read More
Apr 22 2025 | New Joint Scientific Statement on Ejection Fraction Released by Leading Heart Failure Organizations HFSA News In The News Journal of Cardiac Failure Press Release Research Statement Read More
Apr 18 2025 | U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications Industry News In The News Industry Read More
Apr 17 2025 | Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial Industry News In The News Industry Read More
Apr 15 2025 | New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival Industry News In The News Industry Read More
